Angelalign Technology (FRA:77D) Research & Development: €23.8 Mil (TTM As of Dec. 2025)


FRA:77D Angelalign Technology Inc FRA:77D
69 GF Score
Price €8.15
GF Value €11.62
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Angelalign Technology Research & Development?

Angelalign Technology FRA:77D 69 Research & Development is €23.8 Mil as of Dec. 2025. GuruFocus rates FRA:77D with a GF Score™ of 69/100 and a GF Value™ of €11.62 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Angelalign Technology's Research & Development for the six months ended in Dec. 2025 was €12.7 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €23.8 Mil.

Angelalign Technology  (FRA:77D) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Angelalign Technology Research & Development Related Terms

Angelalign Technology Research & Development Historical Data

* Premium members only.

The historical data trend for Angelalign Technology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Angelalign Technology Research & Development Chart

Angelalign Technology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 17.09 20.21 22.60 20.36 23.60

Angelalign Technology Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.71 9.79 10.30 11.11 12.66
FRA:77D
69GF Score
Angelalign Technology Inc FRA:77D
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Angelalign Technology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €23.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €23.8 Mil mean?
Angelalign Technology (FRA:77D) has a Research & Development of €23.8 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Angelalign Technology and its competitors.
Is Angelalign Technology's Research & Development too high?
Angelalign Technology's current Research & Development is €23.8 Mil. Overall, Angelalign Technology has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Angelalign Technology's Research & Development compare to ISRG and BDX?
Angelalign Technology's Research & Development of €23.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Angelalign Technology and its competitors. Angelalign Technology's current Research & Development is €23.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Angelalign Technology stock overvalued right now?
Based on GuruFocus' analysis, Angelalign Technology (FRA:77D) is currently considered Significantly Undervalued. The stock's GF Value™ is €11.62, compared to a current price of €8.15 — trading 29.9% below its estimated fair value. The current Research & Development is €23.8 Mil. Angelalign Technology's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Angelalign Technology (FRA:77D), the current Research & Development is €23.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Angelalign Technology (FRA:77D) Overvalued in 2026?

Based on GuruFocus' analysis, Angelalign Technology stock appears to be undervalued. The current stock price of €8.15 is trading 29.9% below its estimated GF Value™ of €11.62. GuruFocus considers Angelalign Technology to be Significantly Undervalued.

Key valuation signals for FRA:77D:

  • Research & Development: €23.8 Mil
  • GF Value™: €11.62 vs. price of €8.15 (29.9% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the FRA:77D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Angelalign Technology Business Description

Other Exchanges AGLFF:USA06699:Hong Kong
Address No. 500 Zhengli Road, 6th Floor - 7th Floor, Building No. 7, KIC Business Center, Yangpu District, Shanghai, CHN
Angelalign Technology Inc is an investment holding company. It is principally engaged in clear aligner treatment solutions, including treatment planning services, manufacturing, and marketing of clear aligners. The company provides dental professionals with self-developed digital orthodontic solutions. The company's Angelalign clear aligner system facilitates dental professionals throughout the entire clear aligner treatment process, including digitally-assisted case assessment support and treatment planning services, provide dental professionals with digitally-assisted case assessment support and treatment planning services, and helps dental professionals design, review, and modify treatment plans.
69GF Score

Get the complete analysis for FRA:77D

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.15
Price
€11.62
GF Value